Vanflyta
Vanflyta ingredients
| Active ingredient | Strength |
|---|---|
| Quizartinib Dihydrochloride | 26.5 mg/1, 17.7 mg/1 |
What Vanflyta is used for
The FDA lists the approved uses on the official label (below). In the EU, quizartinib is approved as Vanflyta for:
Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Vanflyta
- Generic name
- Quizartinib
- Made by
- Daiichi Sankyo Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA216993
- On the US market since
- 2023
Official information
- Vanflyta prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Quizartinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vanflyta?
Vanflyta (Quizartinib) is a cancer medicine made by Daiichi Sankyo Inc., approved by the US FDA.
What are the ingredients of Vanflyta?
Vanflyta contains Quizartinib Dihydrochloride (26.5 mg/1, 17.7 mg/1).
Is Vanflyta approved in Europe?
The same active substance is approved in the EU as Vanflyta.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA